carnitine has been researched along with Bipolar Disorder in 11 studies
Bipolar Disorder: A major affective disorder marked by severe mood swings (manic or major depressive episodes) and a tendency to remission and recurrence.
| Excerpt | Relevance | Reference |
|---|---|---|
| "l-carnitine had no effect on mean weight loss compared with placebo (-1." | 9.12 | Carnitine does not improve weight loss outcomes in valproate-treated bipolar patients consuming an energy-restricted, low-fat diet. ( Elmslie, JL; Hunt, PJ; Joyce, PR; Mann, JI; Porter, RJ, 2006) |
| "Resolution of hyperammonemia caused by Valproic acid therapy may be enhanced with the administration of L-carnitine." | 8.95 | Sudden valproate-induced hyperammonemia managed with L-carnitine in a medically healthy bipolar patient: Essential review of the literature and case report. ( Ballabio, M; Cattaneo, CI; D'Innella, P; Fornaro, M; Ressico, F; Valsesia, R, 2017) |
| "These findings suggest that carnitine deficiency is associated with the VPA dose and the serum VPA level in patients with bipolar disorder." | 7.96 | Association Between the Serum Carnitine Level and Ammonia and Valproic Acid Levels in Patients with Bipolar Disorder. ( Ishioka, M; Kubo, K; Miyazaki, K; Nakagami, T; Shimoda, K; Sugawara, N; Tarakita, N; Yasui-Furukori, N; Yokoyama, S, 2020) |
| "We sought to compare serum carnitine levels and clinical correlates between stable outpatients and acutely hospitalised individuals with diagnoses of bipolar disorder and schizophrenia." | 7.83 | Comparison of serum carnitine levels and clinical correlates between outpatients and acutely hospitalised individuals with bipolar disorder and schizophrenia: A cross-sectional study. ( Abramson, RK; Breen, RJ; Cuturic, M; Edwards, AC; Levy, EE, 2016) |
| "Valproic acid, a branched short-chain fatty acid, has numerous action mechanisms which turn it into a broad spectrum anticonvulsant drug and make its use possible in some other pathologies such as bipolar disorder." | 7.80 | Hyperammonemia associated with valproic acid concentrations. ( Alvariza, S; Fagiolino, P; Guevara, N; Ibarra, M; Magallanes, L; Maldonado, C; Olano, I; Olmos, I; Vázquez, M, 2014) |
| " Three groups of patients were studied: (A) epileptic under phenytoin monotherapy (n = 31); (B) with bipolar disorder under valproic acid treatment (n = 28); (C) elderly (n = 41)." | 5.22 | Carnitine and/or Acetylcarnitine Deficiency as a Cause of Higher Levels of Ammonia. ( Fagiolino, P; González, R; Guevara, N; Maldonado, C; Queijo, C; Vázquez, M, 2016) |
| "l-carnitine had no effect on mean weight loss compared with placebo (-1." | 5.12 | Carnitine does not improve weight loss outcomes in valproate-treated bipolar patients consuming an energy-restricted, low-fat diet. ( Elmslie, JL; Hunt, PJ; Joyce, PR; Mann, JI; Porter, RJ, 2006) |
| "Resolution of hyperammonemia caused by Valproic acid therapy may be enhanced with the administration of L-carnitine." | 4.95 | Sudden valproate-induced hyperammonemia managed with L-carnitine in a medically healthy bipolar patient: Essential review of the literature and case report. ( Ballabio, M; Cattaneo, CI; D'Innella, P; Fornaro, M; Ressico, F; Valsesia, R, 2017) |
| "Valproic acid is approved for treatment of seizures and manic episodes of bipolar disorder, and continues to be one of the most commonly prescribed antiepileptic drugs in the world." | 4.90 | Evidence for a potential protective effect of carnitine-pantothenic acid co-treatment on valproic acid-induced hepatotoxicity. ( Felker, D; Johnson, DE; Lynn, A; Wang, S, 2014) |
| "These findings suggest that carnitine deficiency is associated with the VPA dose and the serum VPA level in patients with bipolar disorder." | 3.96 | Association Between the Serum Carnitine Level and Ammonia and Valproic Acid Levels in Patients with Bipolar Disorder. ( Ishioka, M; Kubo, K; Miyazaki, K; Nakagami, T; Shimoda, K; Sugawara, N; Tarakita, N; Yasui-Furukori, N; Yokoyama, S, 2020) |
| "We sought to compare serum carnitine levels and clinical correlates between stable outpatients and acutely hospitalised individuals with diagnoses of bipolar disorder and schizophrenia." | 3.83 | Comparison of serum carnitine levels and clinical correlates between outpatients and acutely hospitalised individuals with bipolar disorder and schizophrenia: A cross-sectional study. ( Abramson, RK; Breen, RJ; Cuturic, M; Edwards, AC; Levy, EE, 2016) |
| "Valproic acid, a branched short-chain fatty acid, has numerous action mechanisms which turn it into a broad spectrum anticonvulsant drug and make its use possible in some other pathologies such as bipolar disorder." | 3.80 | Hyperammonemia associated with valproic acid concentrations. ( Alvariza, S; Fagiolino, P; Guevara, N; Ibarra, M; Magallanes, L; Maldonado, C; Olano, I; Olmos, I; Vázquez, M, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Yokoyama, S | 1 |
| Yasui-Furukori, N | 1 |
| Nakagami, T | 1 |
| Miyazaki, K | 1 |
| Ishioka, M | 1 |
| Tarakita, N | 1 |
| Kubo, K | 1 |
| Sugawara, N | 1 |
| Shimoda, K | 1 |
| Cattaneo, CI | 1 |
| Ressico, F | 1 |
| Valsesia, R | 1 |
| D'Innella, P | 1 |
| Ballabio, M | 1 |
| Fornaro, M | 1 |
| Costa, AC | 1 |
| Joaquim, HPG | 1 |
| Talib, LL | 1 |
| Serpa, MH | 1 |
| Zanetti, MV | 1 |
| Gattaz, WF | 1 |
| Felker, D | 1 |
| Lynn, A | 1 |
| Wang, S | 1 |
| Johnson, DE | 1 |
| Vázquez, M | 2 |
| Fagiolino, P | 2 |
| Maldonado, C | 2 |
| Olmos, I | 1 |
| Ibarra, M | 1 |
| Alvariza, S | 1 |
| Guevara, N | 2 |
| Magallanes, L | 1 |
| Olano, I | 1 |
| Queijo, C | 1 |
| González, R | 1 |
| Cuturic, M | 1 |
| Abramson, RK | 1 |
| Breen, RJ | 1 |
| Edwards, AC | 1 |
| Levy, EE | 1 |
| Prohaska, ES | 1 |
| Muzyk, AJ | 1 |
| Rivelli, SK | 1 |
| Elmslie, JL | 1 |
| Porter, RJ | 1 |
| Joyce, PR | 1 |
| Hunt, PJ | 1 |
| Mann, JI | 1 |
| Carr, RB | 1 |
| Shrewsbury, K | 1 |
| Raby, WN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| PSG in Valproate-induced Nocturnal Enuresis in Children[NCT04191863] | 260 participants (Actual) | Observational | 2018-09-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for carnitine and Bipolar Disorder
| Article | Year |
|---|---|
Sudden valproate-induced hyperammonemia managed with L-carnitine in a medically healthy bipolar patient: Essential review of the literature and case report.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Carnitine; Humans; Hyperammonemia; Male; Substance-Relate | 2017 |
Evidence for a potential protective effect of carnitine-pantothenic acid co-treatment on valproic acid-induced hepatotoxicity.
Topics: Animals; Anticonvulsants; Bipolar Disorder; Carnitine; Chemical and Drug Induced Liver Injury; Child | 2014 |
Hyperammonemia due to valproic acid in the psychiatric setting.
Topics: Adult; Aged; Bipolar Disorder; Carnitine; Child; Female; Humans; Hyperammonemia; Liver; Middle Aged; | 2007 |
2 trials available for carnitine and Bipolar Disorder
| Article | Year |
|---|---|
Carnitine and/or Acetylcarnitine Deficiency as a Cause of Higher Levels of Ammonia.
Topics: Acetylcarnitine; Adolescent; Adult; Aged; Aged, 80 and over; Ammonia; Bipolar Disorder; Carnitine; E | 2016 |
Carnitine does not improve weight loss outcomes in valproate-treated bipolar patients consuming an energy-restricted, low-fat diet.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Body Mass Index; Carnitine; Diet, Fat-Restricted; Diet, Re | 2006 |
6 other studies available for carnitine and Bipolar Disorder
| Article | Year |
|---|---|
Association Between the Serum Carnitine Level and Ammonia and Valproic Acid Levels in Patients with Bipolar Disorder.
Topics: Ammonia; Anticonvulsants; Bipolar Disorder; Carnitine; Epilepsy; Female; Humans; Male; Middle Aged; | 2020 |
Plasma metabolites in first episode psychoses.
Topics: Adolescent; Adult; Biomarkers; Bipolar Disorder; Carnitine; Female; Humans; Lysophosphatidylcholines | 2019 |
Hyperammonemia associated with valproic acid concentrations.
Topics: Adolescent; Adult; Ammonia; Bipolar Disorder; Carnitine; Child; Dietary Supplements; Dose-Response R | 2014 |
Comparison of serum carnitine levels and clinical correlates between outpatients and acutely hospitalised individuals with bipolar disorder and schizophrenia: A cross-sectional study.
Topics: Adult; Bipolar Disorder; Carnitine; Cross-Sectional Studies; Female; Hospitalization; Humans; Inpati | 2016 |
Levocarnitine-induced hypophosphatemia in a hemodialysis patient with acute valproic acid toxicity.
Topics: Adolescent; Anticonvulsants; Bipolar Disorder; Carnitine; Drug-Related Side Effects and Adverse Reac | 2012 |
Carnitine for valproic acid-induced hyperammonemia.
Topics: Adult; Ammonia; Bipolar Disorder; Carbamoyl-Phosphate Synthase (Ammonia); Carnitine; Depressive Diso | 1997 |